tradingkey.logo

Check Cap Ltd

CHEK
1.300USD
0.000
Market hours ETQuotes delayed by 15 min
7.61MMarket Cap
LossP/E TTM

Check Cap Ltd

1.300
0.000

More Details of Check Cap Ltd Company

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Check Cap Ltd Info

Ticker SymbolCHEK
Company nameCheck Cap Ltd
IPO dateFeb 19, 2015
CEOMr. Alex Ovadia
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 19
Address29 Abba Hushi Ave.
City
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code3009000
Phone97248303401
Websitehttps://check-cap.com/
Ticker SymbolCHEK
IPO dateFeb 19, 2015
CEOMr. Alex Ovadia

Company Executives of Check Cap Ltd

Name
Name/Position
Position
Shareholding
Change
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Dr. Hanit Brenner-lavie
Dr. Hanit Brenner-lavie
Vice President - Clinical Affairs
Vice President - Clinical Affairs
--
--
Mr. Dan Hilerowitz
Mr. Dan Hilerowitz
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Sat, Aug 30
Updated: Sat, Aug 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
10.86%
Ramanathan (Vijay)
5.13%
Symetryx Corp
4.82%
Citadel Advisors LLC
0.44%
Susquehanna International Group, LLP
0.39%
Other
78.35%
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
10.86%
Ramanathan (Vijay)
5.13%
Symetryx Corp
4.82%
Citadel Advisors LLC
0.44%
Susquehanna International Group, LLP
0.39%
Other
78.35%
Shareholder Types
Shareholders
Proportion
Corporation
15.69%
Individual Investor
5.13%
Hedge Fund
0.61%
Research Firm
0.54%
Investment Advisor
0.48%
Investment Advisor/Hedge Fund
0.17%
Bank and Trust
0.05%
Other
77.34%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
28
129.83K
1.85%
-53.08K
2025Q2
39
1.57M
26.85%
+1.07M
2025Q1
42
1.57M
26.85%
+1.00M
2024Q4
44
1.61M
27.59%
+1.15M
2024Q3
45
1.48M
25.29%
+968.05K
2024Q2
48
1.48M
25.22%
+958.50K
2024Q1
57
722.40K
12.35%
+185.59K
2023Q4
59
777.23K
13.29%
+83.98K
2023Q3
61
699.06K
11.95%
+309.38K
2023Q2
62
22.37K
0.38%
-595.96K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
EquityLine Alternate Assets GP Inc
762.72K
10.86%
--
--
Dec 31, 2024
Ramanathan (Vijay)
360.00K
5.13%
--
--
Dec 31, 2024
Symetryx Corp
338.63K
4.82%
--
--
Dec 31, 2024
Citadel Advisors LLC
31.22K
0.44%
+10.36K
+49.70%
Jun 30, 2025
Susquehanna International Group, LLP
27.58K
0.39%
+27.58K
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
20.14K
0.29%
+300.00
+1.51%
Jun 30, 2025
Virtu Americas LLC
11.76K
0.17%
+11.76K
--
Jun 30, 2025
Two Sigma Investments, LP
11.38K
0.16%
-100.00
-0.87%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.13%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
5.94K
0.08%
+5.94K
--
Jun 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Date
Type
Ratio
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
Nov 23, 2022
Merger
20→1
KeyAI